Double antibody cocktail therapy REGN-COV2: Regenerative elements initiate the first clinical study on COVID-19 for the new coronavirus

Regeneron Pharmaceuticals announced that it has begun the first clinical study on its dual antibody mixture REGN-COV2 for thepreventionand the treatment of new coronavirus
COVID-19The company noted that REGN-COV2 combines two antibodies, REGN10933 and REGN10987, which are non-competitively binding to the receptor binding domain (RBD) of the SARS-CoV-2 virus sting protein to reduce the escape of mutant virusesAccording to Regeneron, the REGN-COV2 clinical program will consist of four independent research groups, including in-patient and non-hospitalized new crown COVID-19infectedpatients, Uninfectedpopulation s
and uninfected people who were in close contact with PATIENTs with COVID-19 in high-risk exposure groupsGeorge Yancopoulos, Regeneron's chief scientific officer, said REGN-COV2 has "the potential topreventand treat COVID-19 infection, and also to prevent the virus from "escaping."